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Even ten years after the passage of the German Genetic Engineering Act (GenTG) 
and the Deliberate Release Directive 90/220/EEC, the debate in Germany and 
Europe generally over the »safety« of genetically modified plants has not abated, 
let alone reached any conclusion. The situation is very different in the Americas. 
In the USA, Canada and Argentina, the second half of the 90s saw increasingly 
widespread cultivation of transgenic maize and rape seed, transgenic soybeans, 
cotton and potatoes, with virtually no sign of public debate over the benefits 
and risks of transgenic plants. At the same time a hostile attitude to »the Green 
genetic engineering revolution« emerged in Europe (and specifically in the UK 
and France), which had previously been apparent mainly in the German-speak-
ing nations.
At the European level, discussions on an amended Deliberate Release Directive 
90/220/EEC had been in progress since 1997. Developments in the EU member 
states culminated at the political level in the summer of 1999 in a de facto mor-
atorium on approval of transgenic plants for marketing by the Council of Envi-
ronmental Ministers, combined with the demand that the reforms in progress be 
completed before any new approvals are issued. Besides various modifications – 
which are still controversial and unresolved as of November 2000 – the amended 
Directive is intended in any case to include the requirement of both case-by-case 
and general longer-term monitoring of the effects of transgenic plants (currently 
generally described as »post-marketing monitoring«).
In Germany, marketing approval for the maize variety Bt176/ »Windsor« (about 
to receive variety approval from the »Bundessortenamt« – German Federal Plant 
Variety Agency) was suspended in February 2000 under Article 16 of the Re-
lease Directive, which constitutes a safeguard clause. This can be applied if new 
findings on potential hazards cast doubt on the original basis for approval. This 
event has sparked off forceful political and scientific controversy in Germany, 
which has also involved the German Bundestag and its committees on a number 
of occasions.
Finally, in June 2000 the German Chancellor announced an initiative seeking to 
agree a three-year transitional phase with the companies involved during which 
commercial cultivation of transgenic plants would be possible only on a lim-
ited scale and in combination with increased research into safety aspects, and 
particularly an intensive monitoring programme. The Federal Ministry of Edu-
cation, Science, Research and Technology had already established a new promo-
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tional key area – »Safety research and monitoring« – in March 2000, intended 
to close specific major gaps in the knowledge of biosafety questions over the 
next two years.
SUBJECT AND OBJECTIVES OF THE PRESENT REPORT
At the suggestion of the Committee on Food, Agriculture and Forestry and as 
resolved by the Committee on Education, Science, Technology and Technolo-
gy Assessment, TAB was commissioned to produce a status report on risk as-
sessment and post-marketing monitoring of transgenic agricultural crop plants 
which specifically covers
> the status in safety research (inc. post-marketing monitoring) and the debate on 
risks,
> the state of regulation and treatment of licensing procedures in the EU for the 
release, marketing and variety licensing of agricultural crop plants,
> the state of implementation of the Novel Food Directive (licensing and label-
ling)
and the implicit possibilities for action in the areas of research, statutory regula-
tion and design of the licensing procedures. In accordance with the commission, 
it is not the purpose of this report to provide a novel answer to the outstanding 
questions on the safety of handling transgenic plants or develop separate pro-
posals for post-marketing monitoring. Instead, the aim is to supply a focused 
overview of the status of the scientific and political debate. In this process, par-
ticular attention is paid to aspects of the subjects and associated questions which 
are likely to become increasingly important in future.
STATUS OF THE SCIENTIFIC DEBATE ON RISKS
There has been general consensus in science and politics for some years on the 
basic strategy for safety research and risk assessment for genetically modified 
plants. In principle, based on scientific findings, plausible assumptions and sce-
narios, each individual trait is subjected to (case-by-case) risk assessment, and 
experience with the genetically modified organism is built up in a step-by-step 
process. In contrast to this consensus on the logical phases in risk determination, 
there is still scientific and political controversy about the interpretation of the 




General environmental impacts, which have been debated for many years and 
are covered under the licensing procedure, are gene transfer to wild relatives and 
hybridization (vertical gene transfer) and horizontal gene transfer. These pro-
cesses can occur irrespective of the nature of transgenic characteristics (although 
possibly influenced by these) and could potentially mean uncontrolled and ir-
reversible spreading of the plants (keyword: non-reversibility) or at least the 
transgenic trait. A common feature of all three events is that research in release 
experiments is subject to very tight limits. In addition, these are very basic but 
more or less nonspecific biological phenomena which are dependent on a large 
number of interactive factors, and despite research (over decades, in some cases) 
many aspects are only incompletely understood.
A second level of consideration relates to the specific effects of the transgenes, 
e. g. herbicide, insect or virus resistance or modified components on the relevant 
(agricultural) ecosystem. The fact that they proceed by definition from the in-
dividual transgenic traits means that the possible impact chains are more acces-
sible to study on a limited scale, in the laboratory or greenhouse or in release 
experiments, than the general environmental impacts. Besides development of 
resistance by pests, possible impacts which could become increasingly important 
in future are in particular so-called abiotic resistance, or tolerance which would 
offer a clear increase in fitness outside agricultural areas.
Controversies regarding both general and specific impacts relate primarily to 
three different levels.
> first, the fundamental likeliness of occurrence (e. g. of outcrossing or develop-
ment of resistance by insect pests),
> second, the degree of possible damage (e. g. reducing biological diversity or 
adversely affecting organic farming), and
> third, the possible or necessary measures to avert risk (e. g. size of the protec-
tive zones around fields with transgenic plants or design of resistance manage-
ment).
Science – and hence biological safety research – is concerned strictly speaking 
with identifying and calculating the likelihood of occurrence of specific events, 
and whether the event being studied or anticipated represents damage is a ques-
tion that takes us into the realm of value judgements. A failure to distinguish 
between these two levels often leads to confusion and particularly acrimonious 
and virtually irreconcilable disputes, for example on risk assessment in approval 
procedures for transgenic plants.
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Generally, the state of data appears deficient in many respects, as while there 
have now been over 1,300 release experiments in Europe alone, fewer than 1% 
of release experiments worldwide have been linked with accompanying ecologi-
cal research (although in Germany the figure is 15%). Another reason why there 
is virtually no »real knowledge about risk« is the safety requirements needed for 
the accompanying ecological research. Critical voices point out that the lack of 
evidence of adverse ecological impacts suggests more that the wrong questions 
are being asked (with a resulting lack of corresponding studies) than the absence 
of any risk. Conversely, it is true that conventionally bred plants (i.e. not using 
genetic engineering) have never been subjected to biological safety testing, so 
that the impacts of transgenic varieties are always more thoroughly researched 
than those of conventional varieties. Many scientists also stress that the new 
characteristics of transgenic plants are in principle much more clearly defined – 
and hence more easily documented and researched – than the results of conven-
tional breeding.
It is undoubtedly necessary to continue and intensify safety research in order to 
reduce the major gaps in our knowledge of the possible impacts of cultivating 
transgenic plants. This applies to the plants already developed to the point of 
practical application, and a fortiori to the new varieties with altered composition 
of contents on which the principle of »substantial equivalence« can no longer be 
applied. A decision on which studies have priority always requires consideration 
by scientists and the promotional institutions in the light of the current state of 
knowledge. One problem which currently seems to be getting little attention is 
the problem of new marker genes or systems, which are intended to replace the 
antibiotic resistance genes currently used and which have to be thoroughly test-
ed before use in transgenic food plants.
However, a whole series of questions will in any event be impossible to answer in 
research projects with a limited life. First, the results of scientific research always 
generate not only answers but also new questions, and second because long-term 
indirect or effects can generally only be observed in the course of longer-term 
cultivation of transgenic plants on a significant scale. This realisation has led 
over the past few years to virtual unanimity among all involved on the develop-
ment and implementation of long-term monitoring of transgenic plants under 
cultivation.
With respect to use as food, transgenic plants are studied particularly for pos-
sible health risks, for toxicity and allergenicity. Both properties have previous-
ly been described following the principle of »substantial equivalence«, i.e. on 
the basis of comparison with non-transgenic plants of the same variety. Apart 
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from fundamental criticism of the concept (which has been voiced repeatedly), 
the development of transgenic plants with changed (primary) composition or 
moving towards »health-promoting« transgenic foods has been the subject of 
intensive scientific debate in the past year. For example, in the framework of the 
last G8 summit the OECD – which helped develop and promote the concept of 
»substantial equivalence« – launched a broad-based initiative to reconsider the 
concept and the general treatment of risk assessment for transgenic plants.
RISK ASSESSMENT IN THE APPROVAL PROCEDURES
A question of central political importance on the issue of transgenic plants is the 
regulation of marketing or approval. The (European) approval procedure pro-
vides for risk analysis in which the data provided by the applicant on relevant 
safety aspects of the plant variety in question is reviewed and evaluated on the 
basis of current scientific knowledge and opinion. Approval can only be issued if 
no damaging impacts on humans or the environment are to be expected. As the 
state of scientific knowledge and opinion is still very incomplete and will prob-
ably remain so for some time, decisions on evaluation must be taken in many 
respects without the benefit of reliable or unambiguous scientific information. 
There is also considerable latitude as a result of differing normative require-
ments, assumptions and objectives.
The present report looks in detail at how far the status of the scientific risk 
debate, and specifically the ecological aspects, is taken into account in the opin-
ions in the framework of the approval procedures for marketing under Directive 
90/220/EEC of both the EU scientific committees and national agencies (in Ger-
many, Austria, the UK and – in part – Sweden), and how differences identified in 
the opinions can be explained. It is clear that
> scientific contributions and arguments have been very much selectively used 
and variously interpreted,
> diverging conclusions have been drawn from gaps and areas of uncertainty in 
our knowledge, and
> above all, the possible consequences have been very differently evaluated in 
terms of the scale of damage and resulting implications.
In the core or target questions for risk assessment (and hence the entire approv-
al procedure) on which possible consequences of marketing transgenic plants 
qualify as damaging impacts and which impacts are acceptable or unacceptable, 
6
SUMMARY
the differing normative standards of the various countries make themselves par-
ticularly felt:
> Germany and the UK assess the acceptability of an ecological risk in the context 
of conventional agricultural practice. The assessment is whether a transgenic 
plant poses an additional or greater risk compared with conventional practice; 
if not, the possible impact is regarded as acceptable. By this standard, most of 
the disputed consequences appear entirely acceptable. German court rulings 
define the term »damaging impact on the environment in its interactions« rela-
tively narrowly. This covers only direct impacts, and not indirect or long-term 
impacts.
> By contrast, Sweden and Austria take as the standard »sustainable agriculture«, 
i.e. in this case agriculture with a minimum possible use of »chemicals« and an 
ecological orientation, where Austria also explicitly includes socio-economic 
considerations which within the meaning of Directive 90/220/EEC have so far 
not been considered or are not required in risk assessment. This results in most 
cases in rejection of approval applications, even if the likelihood of occurrence 
of possible damage is regarded as minor but impossible to determine more ac-
curately.
As the choice of these standards constitutes a normative political act, science can 
only provide limited assistance. The political institutions should accept more 
fully and subsequently act on the recognition that science – and specifically sci-
entific policy advice – is able less to close gaps in our knowledge and so derive 
recommendations for action than to identify these gaps in our knowledge, make 
the underlying scientific controversies more transparent, and so characterise the 
political and social scope for action and design.
The actual political challenge lies in a fundamental and »sustainable« improve-
ment in the approval procedures. Irrespective of the specific amendment to the 
Deliberate Release Directive 90/220/EEC, all those involved in the debate about 
the risks of transgenic plants should make a particular effort to distinguish sci-
entific statements (about the likelihood of events) from subjective and basically 
political assessments in terms of content and argument, or at least to label these 
accordingly.
STATUTORY PROVISIONS AND AMENDMENTS
The Deliberate Release Directive 90/220/EEC has been subject to criticism from 
all quarters since its adoption. Key points in the debate were and are:
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> the concept of risk assessment and definition of damage,
> the relationship between horizontal and sectoral regulation,
> centralised approval procedure for the EU,
> time limit on approval for marketing,
> introduction of post-marketing monitoring,
> (GE-specific) provisions on liability,
> labelling for all products, and
> public involvement in the approval procedure.
This Directive has been under review since 1997, and the process of amendment 
is now very advanced. Only a few controversial points are still involved in medi-
ation between the European Parliament, Commission and Council. This means 
that there is very limited scope now for influencing the results of the amendment 
process.
After the amended Directive is adopted, this will have to be enacted in German 
GE law, i.e. an amendment to the German Genetic Engineering Act will be re-
quired.
In addition to implementing the amended EU Directive, a number of unresolved 
questions have been identified which imply the following possibilities for action:
> Identifying and evaluating indirect and long-term impacts will in future play 
an important role in release and marketing approvals. A number of funda-
mental research projects are required here to provide at least partial answers 
and avoid leaving questions entirely to post-marketing monitoring. Within the 
framework of the »Safety research and monitoring« promotional key area in 
the German Federal Government’s program »Biotechnology 2000«, a new key 
topic »Fundamentals, methodology and models for assessing indirect and long-
term impacts of transgenic plants« should accordingly be set up.
> A range of agronomic properties of transgenic agricultural plants (specifically 
herbicidal tolerance and insect resistance) will require resistance management. 
Marketing approval under the amended Directive will probably only be pos-
sible with corresponding restrictions. For appropriate resistance management 
the relevant optimal management strategy and resistance monitoring will have 
to be determined. Just as important are organisational questions and approa-
ches for monitoring. The competent specialist agencies should be given the 
capability to carry out the necessary research work and concept development.
> In the next few years a new generation of transgenic plants is expected cha-
racterised specifically by modified composition, and part of which will qualify 
as functional foods. The impacts on human health, and specifically also the 
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indirect and longer-term nutritional impacts, will accordingly pose entirely new 
questions. Here, the foundations for risk analysis and assessment should be 
established as early as possible, and corresponding research activities initiated.
> Even after the amendment, there will still be no definition of damaging im-
pacts, so that there will still be considerable scope for different assessments. 
Not least, the question will be which agricultural paradigm the impacts of 
GE agricultural plants are measured against. It will not be possible to derive a 
normative framework for this paradigm simply from the debate about GE ap-
plications: instead, this will require a serious definition and specification of the 
term »sustainable agriculture« as a stated goal of European agricultural policy.
> In the EU (and hence in Germany), horizontal and vertical regulations coexist 
in the field of GE applications. In future there will also be a need to reconcile 
the amended Directive 90/220/EEC and the Novel Food Regulation EC/258/97. 
With regard to human health, these two regulatory instruments should as far as 
possible require the same testing procedures, criteria and standards. As far as 
possible, duplicate assessments should be avoided. In the process of optimised 
consultation, the German Federal government should assist the EU Commissi-
on and for this purpose submit its own proposals.
> The debate over establishing a central assessment or even approval procedure 
will be continued in the medium and long term. Corresponding discussion of 
or initial identification of the German position seems to be required.
POST-MARKETING MONITORING
In the last few years, the view has increasingly gained ground that comprehen-
sive marketing of transgenic agricultural plants and the associated large-scale 
cultivation should be accompanied by strategic study and longer-term moni-
toring (in addition to case-by-case risk assessment and stepwise release into the 
environment) of long-term and possibly indirect and unanticipated impacts on 
humans and the environment which cannot be ruled out. The amended Deliber-
ate Release Directive 90/220/EEC will in all likelihood require not only general 
surveillance but also case-specific monitoring. In Germany, the terms in-cultiva-
tion monitoring and general environmental monitoring of transgenic plants have 
established themselves, although not as synonyms.
In post-marketing monitoring, three dimensions or distinctions have special rel-
evance:
> monitoring based on cause-and-effect hypotheses (even if partly unexplained 
or uncertain) versus unexpected or rare events,
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> surveys of the agricultural ecosystem (and adjoining marginal structures) ver-
sus surveys of the environment generally,
> monitoring for limited periods versus long-term or unlimited monitoring.
In Germany proposals and contributions on objectives and concepts, priorities 
and areas for survey and possible implementation stages have been submitted by 
various top Federal agencies, working groups, scientific institutions and interest 
groups. The state of work and debate is characterised by the situation that all 
relevant areas have been identified, the necessary status-quo analyses completed 
and the first steps taking in operationalisation for the majority of relevant as-
pects in the relevant working parties, although full agreement and joint propos-
als have not yet been achieved.
The state of concept development, the corresponding research work and the un-
settled questions give rise to short-term and long-term need or opportunities for 
action. The following political decisions should be made relatively soon:
> Definition of terms and operationalisation of objectives: There is currently no 
consensus among the working groups and institutions involved about the de-
finition and objectives of post-marketing monitoring. The various terms used 
with respect to monitoring and its sub-areas need to be clearly and uniformly 
defined. Based on the preliminary work, definitions and the scope and objecti-
ves of monitoring should also be politically established.
> Decisions on responsibilities and funding: The responsibilities for data collec-
tion, analysis, consolidation and documentation and data evaluation need to 
be clarified. Specifically, it is necessary to determine where the central coordi-
nation unit should be located and what authority it should have. With respect 
to funding it must be determined which costs (or what part thereof) should be 
born by applicants and which by the Federal and Länder authorities.
> Public information and involvement: Public interest in the concept for and de-
sign and results of post-marketing monitoring can be expected to grow. Based 
on initial approaches, public involvement should be developed in informati-
on and debate on concepts for monitoring, in analysing and providing results 
from monitoring and in information and debate on the consequences of the 
results of monitoring.
Longer-term problem and design areas which should be tackled:
> Limiting post-marketing monitoring to pre-marketing safety research and risk 
assessment: A review and assessment of any adverse effects of GMOs takes 
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place before release and marketing as part of the approval procedure. Monito-
ring should supplement the precautionary principle in the approval procedure 
by documenting unexpected and indirect impacts. An important controver-
sy will develop regarding the question of which gaps in our knowledge and 
uncertainties in assessment in the context of pre-marketing safety research and 
risk assessment need to be resolved, and which questions can be postponed in 
future to post-marketing monitoring. The clearest possible distinction should 
be developed between these two areas.
> Criteria for the incorporation of results from monitoring in the approval proce-
dure: If adverse GE-specific effects are observed during monitoring, this should 
lead to action in the cultivation process. This action may also lead to a modi-
fication or withdrawal of marketing approval. Assessment of monitoring data 
can be expected to become a highly contentious future area of conflict. To be 
able to evaluate phenomena for their relevance to safety under the German 
Genetic Engineering Act, corresponding criteria must be developed. The deve-
lopment of a concept for evaluation supported by various groups is a highly 
important task, but also one which is extremely demanding and difficult to 
manage.
Work must be continued within the existing working groups on developing tech-
nical, substantial and organisational aspects. Specifically, proposals must be for-
mulated on concrete survey areas, monitoring parameters, test designs, sample 
grids and data collection, recording methods, controls and reference locations, 
data documentation etc. In addition, cooperation should be sought with other 
European states in order to avoid duplicating work, to benefit from experience 
in other countries, and to arrive at as closely coordinated an approach as possi-
ble in the EU states.
EXPERIENCE WITH THE NOVEL FOOD REGULATION
The Novel Food Regulation (258/97/EC) went into effect in the EU member 
states on 15 May 1997. Since this date, various foods defined as »novel« have 
been subject to special regulations in addition to the general legislation on food. 
In particular, a mandatory safety assessment before marketing and specific label-
ling were introduced. To date, genetically engineered foods (one of several cate-
gories of novel foods) have remained at the focus of public interest and vigorous 
social controversy.
So far, ten products made of various genetically modified maize and rape seed 
varieties have received notification, i.e. after determining their »substantial 
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equivalence«, no separate safety assessment was made for these. Conversely, no 
single food from a transgenic plant has been approved to date in an approval 
proceeding under the Novel Food Regulation. Only a few applications were 
filed, and there are only two cases where opinions have been issued by the Sci-
entific Committee on Food or national agencies.
So far, no uniform practice in procedure and decision-making has emerged in 
notification and approval proceedings under the Novel Food Regulation. How-
ever, experience to date indicates that the Novel Food Regulation and Commis-
sion recommendations on the documentation required for a safety assessment 
form in principle a suitable statutory and procedural framework for reviewing 
novel foods for safety to health. By contrast, there are deficiencies in the scope, 
coverage and methodology of the safety assessment and the interpretation of the 
data available for this, which creates scope for interpretation. This will become 
particularly relevant if the requirements for the safety assessment are raised for 
future novel foods, e. g. foods consumed raw, or novel foods with modified in-
gredients.
Although raw materials and intermediate products based on maize or soybeans 
partly from GMOs are also imported into the EU and processed here, there are 
only isolated instances of labelled products. The labelling requirements which 
have been in force since May 1997 have so far not been able to help consumers 
recognise the actual use of GE raw materials. There are various reasons for this, 
which are discussed in the report.
Implementation to date of the Novel Food Regulation indicates a range of ap-
proaches for addressing problems and deficiencies in implementation:
> For the area of genetically engineered food as a subgroup of »novel« foods 
under the Novel Food Regulation:
     •    one problem with the Novel Food Regulation is that very different 
 catego ries of food are covered jointly. The recommendations of the EU  
 Commission on safety assessment of novel foods should be made more  
 precise with regard to specific guidelines for foods from GMOs.
      •    The exemption of additives and aromas from the coverage of the Novel  
 Food Regulation is criticised in some quarters for the fact that this exclu- 
 des manufacture-specific aspects of these (e. g. GE manufacture) from 
 the safety assessment. If this is regarded as relevant, additives and 
 aromas from GMOs (and specifically from GE plants) should be 
 regulated on the same principles and at the same level of safety as 
 comparable ingredients or foods.
12
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> With respect to notification of foods and ingredients from GE plants:
     •    So far there have been differences in interpretation of the criteria used to
  infer »substanti al equivalence« as a basis for notification. To change this
  situation, clear, uniform and binding criteria should be established under
   which notification without specific safety assessment is sufficient.
      •    If transgenic plants are not approved in the EU and the safety assessment  
 is not yet completed, notification should only be made exceptionally for  
 novel foods from these GE plants.
      •    The current design of the notification procedure violates requirements for 
 openness and transparency, recognised as important principles at least 
 since the EC Commission White Paper on food safety. With the exception 
 of the UK, neither the applications nor the initial review by a national 
 agency are open to public inspection. Applications and opinions should be
   publicly accessible.
> With respect to approval procedure for foods and ingredients from GE plants:
     •    In the comparison between novel and conventional food, the emphasis 
 is on specific components which are informative and characteristic of the 
 relevant plant. Unintended side-effects relevant to health in the GE plants 
 only attract attention if they fall within the range of studied components 
 and lead to noteworthy changes in concentrations there. To reduce uncer-
  tainty here, recommendations should be formulated on the range of com-
  ponents used for comparison (nutrients, toxins, antinutrients) which are 
 appropriate for the plant species in question. In addition, international 
 databases should be set up of variety-specific and species-specific 
 information on the components required to determine the equivalency 
 status of a GMO product and its natural variations due to location, 
 climaticzone, cultivation techniques and species. Another approach would 
 be to develop new methods which document patterns of substances which 
 might allow conclusions regarding unexpected secondary effects, rather 
 than specific individual substances.
      •    The European Food Agency proposed by the EU Commission should help 
 improve risk analysis substantially, for which purpose it will need 
 corresponding material funding. Its job should be to collect systematically 
 all the data and information relevant to safety assessment, to coordinate 
 the further development of scientific methods and advice from expert 
 panels (scientific committees) with particular emphasis on maintaining 
 openness and transparency.
> With regard to the deficiencies in labelling presented above:
      •    Enforcing the existing labelling duty: Compliance with existing rules must 
  be ensured. Appropriate sanctions should be considered for violations. Le-
  gal certainty should be enhanced by defining relevant current, standardised
13
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  test procedures.
      •    Transferring the level of proof to ingredients: If evidence of a GMO requi-
  ring labelling is shifted from the final product to the level of individual in-
  gredients, this would expand the number of actually labelled foods. On the
   one hand, this would substantially increase the effort in labelling and mo-
  nitoring it, on the other hand it could improve the information contained
   in the labelling.
      •    Partial abandonment of evidentially-based labelling for specific ingredients
   characteristic of a product: The use of genetic engineering in producing 
 a food only results in labelling if this food (or the ingredients) can be
  shown to contain GMO-specific material. This situation could only be  
 changed if abandonment were planned of evidentially-based labelling. 
 Actual use of GE plants in the production of food could only be better 
 reflected if labelling (at least for characteristic ingredients) were no longer 
 based on evidence of GMOs. The »evidential gap« would then have to be 
 closed by a system of documentation tracking the products.
      •    In view of the limited coverage of mandatory labelling regulations, 
 supplementary information concepts close to the product should be 
 developed and implemented by the food industry generally. Information 
  can help counter the widespread uncertainty among consumers. To put 
 such projects on the broadest possible social basis it is advisable to involve 
 a range of actors, such as consumer associations, universities and other 
 scientific institutions in their conception and implementation. State 
 institutions could act as initiators and moderators.
OUTLOOK
The future of Green genetic engineering in Europe seems virtually impossible 
to assess in the autumn of 2000. On the one hand there is the expectation of 
applicants that the pending approval procedures for marketing transgenic ag-
ricultural plants will be resumed soon and that conflicts will be substantially 
reduced as a result of the adoption of a revised Deliberate Release Directive. On 
the other hand there is the warning or hope that the current »blockade« in the 
EU on marketing transgenic plants will continue for years.
A new generation of transgenic plants with modified composition and potential-
ly health-promoting properties (particularly the so-called functional foods) is ex-
pected to reduce or even eliminate consumer reservations about GE food. These 
second-generation transgenic plants will, however, pose entirely new questions 
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in safety assessment, and their health benefits will probably be strongly disput-
ed. There is accordingly no foreseeable end to controversy here.
The continuation and expansion of safety research and the introduction of 
monitoring will increase our knowledge of transgenic plants and reduce exist-
ing gaps in it. At the same time, however, it is likely that new and unresolved 
questions will arise on the possible impacts of cultivation of transgenic plants, 
and that results will be interpreted in different ways. Experience to date shows 
that »surprises« (i.e. unforeseen ecological or economic impacts) must always 
be expected. A realistic appraisal is very important for the general perception. 
Safety questions should not be described as answered or answerable in the near 
future unless the state of the data and our knowledge is correspondingly secure.
The following conclusions can be drawn from this situation:
> No excessive expectations should be raised for the amended Deliberate Re-
lease Directive 90/220/EEC and the introduction of post-marketing monito-
ring. Their potential for resolving problems will inevitably remain limited until 
such time as fundamental agreement is reached on definitions of damage and 
desirable agricultural practice.
> Both the amended Deliberate Release Directive and the Novel Food Regulation 
require operationalisation and specific guidelines for implementing the safety 
assessment and approval procedures. This is the only way to reduce discussions 
about the scope, coverage, methodology and interpretation of the safety assess-
ments. This should build on the current state of the scientific risk debate. To 
this extent it will be an ongoing task, rather than a one-time exercise.
> New instruments – such as post-marketing monitoring or revised labelling re-
gulations – should only be introduced when their integration into existing sta-
tutory provisions and their implications have been carefully considered and 
widely discussed. To avoid new areas of conflict and controversy, e. g. in post-
marketing monitoring a distinction should be made as early as possible between 
this and pre-marketing safety research and risk assessment and the criteria for 
incorporating information from monitoring in the approval procedure should 
be clarified.
> Finally, new areas of conflict should be identified at the earliest possible state 
and investigated in advance. Attention is drawn particularly to the announced 
second-generation transgenic plants, which are e. g. supposed to have a health-
promoting effect as »functional food«. These will probably result in a shift in 
the debate from possible ecological impacts towards potential health impacts 
and also pose entirely new and possibly even greater problems in safety assess-
ment than the current transgenic plants.
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